Cannabis and Hemp Industry Investment News
SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., as an independent director to the Company's b...
SAN DIEGO, CA, June 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has expanded its Clinical Advisory Board with the appointment of ophthalmology e...
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, has successfully completed genotoxicit...
's () Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortes...
The 1,679,000 warrants were issued in the final week of May and were each exercised into one common company share at C$0.75 The warrants had been set ...
EXMceuticals said that the deal will create a new company in the “fast-growing” business segment of hemp and cannabinoid-based product distribution Fo...
It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun The first trial is a ra...
Lexaria provided Amari with its DehydraTECH technology, which delivers CBD to the body more quickly and effectively than traditional formulations Hund...
The new study programs will target NSAIDs, nicotine replacement therapies, tetrahydrocannabinol (THC), and erectile dysfunction Each study will evalu...
The maker of hard pill cannabinoid formulations said it can now fulfill the purchase order received from Australian hemp and medical cannabis group Ca...
Lexaria Bioscience (CSE: LXX- Nasdaq: LEXXW) CEO Chris Bunka joined Steve Darling from Proactive to share news the company has released positive resul...
The company reported that by using its DehydraTECH technology CBD beverages demonstrated 93.4% potency one year after production Lexaria's first paten...
Two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of a SARS-CoV-2 infected human cell culture study (VIRA...
Lexaria Bioscience (CSE: LXX-NASDAQ: LEXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive to share details about the company’s three h...
In human study HYPER-H21-1, the recruiting of 24 volunteers with otherwise untreated pre- or mild-hypertension has begun, and dosing using a single 30...
Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the Australian Patent Office has gr...
In addition, the company has received an initial purchase order of $406,200 with its Australian partner, Cann Global Limited Cann Global will particip...
The company said the merger will create a leading company in the distribution of hemp and cannabinoid-based products, which will operate under the Glo...
The company said it has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the company a...
Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March...
